BDSX vs. TALK, EHAB, INNV, CELC, SBC, PSNL, VMD, DCGO, LFMD, and AIRS
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Talkspace (TALK), Enhabit (EHAB), InnovAge (INNV), Celcuity (CELC), SBC Medical Group (SBC), Personalis (PSNL), Viemed Healthcare (VMD), DocGo (DCGO), LifeMD (LFMD), and AirSculpt Technologies (AIRS). These companies are all part of the "healthcare" industry.
Biodesix vs.
Talkspace (NASDAQ:TALK) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.
Talkspace has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.
In the previous week, Talkspace had 2 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Talkspace and 4 mentions for Biodesix. Biodesix's average media sentiment score of 1.06 beat Talkspace's score of 0.67 indicating that Biodesix is being referred to more favorably in the news media.
Biodesix received 25 more outperform votes than Talkspace when rated by MarketBeat users. Likewise, 75.00% of users gave Biodesix an outperform vote while only 38.46% of users gave Talkspace an outperform vote.
Talkspace has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Talkspace currently has a consensus price target of $4.38, indicating a potential upside of 66.35%. Biodesix has a consensus price target of $2.95, indicating a potential upside of 340.30%. Given Biodesix's higher possible upside, analysts plainly believe Biodesix is more favorable than Talkspace.
57.4% of Talkspace shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 21.7% of Talkspace shares are held by insiders. Comparatively, 69.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Talkspace has a net margin of 0.61% compared to Biodesix's net margin of -66.84%. Talkspace's return on equity of 0.98% beat Biodesix's return on equity.
Summary
Talkspace beats Biodesix on 12 of the 18 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy BDSX Stock Free BDSX Stock Alerts